SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-23-046152
Filing Date
2023-08-16
Accepted
2023-08-16 20:53:51
Documents
1
Period of Report
2023-08-16

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 6565
  Complete submission text file 0001209191-23-046152.txt   8083
Mailing Address C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902
Business Address
Stalfort John A III (Reporting) CIK: 0001709418 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39536 | Film No.: 231179642

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Issuer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)